Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jerrold Frank Rosenbaum, M.D.

Co-Author

This page shows the publications co-authored by Jerrold Rosenbaum and Maurizio Fava.
Connection Strength

8.330
  1. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol. 2005 Oct; 25(5):441-7.
    View in: PubMed
    Score: 0.326
  2. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol. 2002 Aug; 22(4):379-87.
    View in: PubMed
    Score: 0.262
  3. Fenfluramine challenge in unipolar depression with and without anger attacks. Psychiatry Res. 2000 Apr 24; 94(1):9-18.
    View in: PubMed
    Score: 0.224
  4. Anxiety disorders in major depression. Compr Psychiatry. 2000 Mar-Apr; 41(2):97-102.
    View in: PubMed
    Score: 0.222
  5. Anger attacks in patients with depression. J Clin Psychiatry. 1999; 60 Suppl 15:21-4.
    View in: PubMed
    Score: 0.204
  6. Anger attacks in depression. Depress Anxiety. 1998; 8 Suppl 1:59-63.
    View in: PubMed
    Score: 0.191
  7. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine. Am J Psychiatry. 1997 Dec; 154(12):1760-2.
    View in: PubMed
    Score: 0.190
  8. Major depressive subtypes and treatment response. Biol Psychiatry. 1997 Oct 01; 42(7):568-76.
    View in: PubMed
    Score: 0.187
  9. Eating disorder symptomatology in major depression. J Nerv Ment Dis. 1997 Mar; 185(3):140-4.
    View in: PubMed
    Score: 0.180
  10. A preliminary study on the efficacy of sertraline and imipramine on anger attacks in atypical depression and dysthymia. Psychopharmacol Bull. 1997; 33(1):101-3.
    View in: PubMed
    Score: 0.178
  11. Hostility changes following antidepressant treatment: relationship to stress and negative thinking. J Psychiatr Res. 1996 Nov-Dec; 30(6):459-67.
    View in: PubMed
    Score: 0.176
  12. Patterns of personality disorder comorbidity in early-onset versus late-onset major depression. Am J Psychiatry. 1996 Oct; 153(10):1308-12.
    View in: PubMed
    Score: 0.175
  13. Gender differences in Axis I comorbidity among depressed outpatients. J Affect Disord. 1996 Jun 05; 38(2-3):129-33.
    View in: PubMed
    Score: 0.171
  14. Fluoxetine treatment of anger attacks: a replication study. Ann Clin Psychiatry. 1996 Mar; 8(1):7-10.
    View in: PubMed
    Score: 0.168
  15. Cardiovascular risk factors in depression. The role of anxiety and anger. Psychosomatics. 1996 Jan-Feb; 37(1):31-7.
    View in: PubMed
    Score: 0.166
  16. Hypothyroidism and hyperthyroidism in major depression revisited. J Clin Psychiatry. 1995 May; 56(5):186-92.
    View in: PubMed
    Score: 0.159
  17. Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry. 1995 Feb; 56(2):52-5.
    View in: PubMed
    Score: 0.156
  18. Gender differences in hostility among depressed and medical outpatients. J Nerv Ment Dis. 1995 Jan; 183(1):10-4.
    View in: PubMed
    Score: 0.155
  19. Personality disorder comorbidity with major depression and response to fluoxetine treatment. Psychother Psychosom. 1994; 62(3-4):160-7.
    View in: PubMed
    Score: 0.145
  20. Dysfunctional attitudes in major depression. Changes with pharmacotherapy. J Nerv Ment Dis. 1994 Jan; 182(1):45-9.
    View in: PubMed
    Score: 0.145
  21. Psychopharmacology of pathologic aggression. Harv Rev Psychiatry. 1993 Nov-Dec; 1(4):244-6.
    View in: PubMed
    Score: 0.143
  22. Are thymoleptic-responsive "anger attacks" a discrete clinical syndrome? Psychosomatics. 1993 Jul-Aug; 34(4):350-5.
    View in: PubMed
    Score: 0.140
  23. Suicidality and fluoxetine: is there a relationship? J Clin Psychiatry. 1991 Mar; 52(3):108-11.
    View in: PubMed
    Score: 0.119
  24. "Anger attacks": possible variants of panic and major depressive disorders. Am J Psychiatry. 1990 Jul; 147(7):867-70.
    View in: PubMed
    Score: 0.113
  25. Assuring that double-blind is blind. Am J Psychiatry. 2010 Mar; 167(3):250-2.
    View in: PubMed
    Score: 0.111
  26. The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. J Clin Psychiatry. 2008 Oct; 69(10):1513-28.
    View in: PubMed
    Score: 0.101
  27. Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes. Psychother Psychosom. 2007; 76(1):40-6.
    View in: PubMed
    Score: 0.089
  28. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006 Nov; 163(11):1905-17.
    View in: PubMed
    Score: 0.088
  29. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. 2005 Dec; 8(4):523-8.
    View in: PubMed
    Score: 0.079
  30. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol. 2005 Jun; 8(2):215-21.
    View in: PubMed
    Score: 0.076
  31. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol. 2005 Mar; 8(1):59-63.
    View in: PubMed
    Score: 0.076
  32. Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. J Clin Psychopharmacol. 2004 Aug; 24(4):467-9.
    View in: PubMed
    Score: 0.075
  33. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry. 2004 Aug; 65(8):1090-5.
    View in: PubMed
    Score: 0.075
  34. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry. 2004 Aug; 65(8):1096-8.
    View in: PubMed
    Score: 0.075
  35. Effect of medical comorbidity on response to fluoxetine augmentation or dose increase in outpatients with treatment-resistant depression. Psychosomatics. 2004 May-Jun; 45(3):224-9.
    View in: PubMed
    Score: 0.074
  36. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004 Feb; 65(2):217-21.
    View in: PubMed
    Score: 0.073
  37. A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatment. Depress Anxiety. 2004; 19(1):43-50.
    View in: PubMed
    Score: 0.072
  38. Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day. Acta Psychiatr Scand. 2003 Dec; 108(6):432-8.
    View in: PubMed
    Score: 0.072
  39. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry. 2003 Nov 01; 54(9):879-83.
    View in: PubMed
    Score: 0.071
  40. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003 Jun; 26(2):457-94, x.
    View in: PubMed
    Score: 0.069
  41. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry. 2003 Jun 01; 53(11):1028-42.
    View in: PubMed
    Score: 0.069
  42. Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):137-45.
    View in: PubMed
    Score: 0.069
  43. Comparing anxiety disorders and anxiety-related traits in bipolar disorder and unipolar depression. J Psychiatr Res. 2003 May-Jun; 37(3):187-92.
    View in: PubMed
    Score: 0.069
  44. Behavioral and emotional disturbances in the offspring of depressed parents with anger attacks. Psychother Psychosom. 2003 Mar-Apr; 72(2):102-6.
    View in: PubMed
    Score: 0.068
  45. Fluoxetine treatment of depressed patients with comorbid anxiety disorders. J Psychopharmacol. 2002 Sep; 16(3):215-9.
    View in: PubMed
    Score: 0.066
  46. Body dysmorphic disorder in outpatients with major depression. J Affect Disord. 2002 May; 69(1-3):141-8.
    View in: PubMed
    Score: 0.064
  47. Strategies for treatment of SSRI-associated sexual dysfunction: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 2002 Mar-Apr; 10(2):109-14.
    View in: PubMed
    Score: 0.064
  48. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jan; 26(1):177-87.
    View in: PubMed
    Score: 0.063
  49. Tryptophan depletion in SSRI-recovered depressed outpatients. Psychopharmacology (Berl). 2001 May; 155(2):123-7.
    View in: PubMed
    Score: 0.060
  50. A survey of prescribing preferences in the treatment of refractory depression: recent trends. Psychopharmacol Bull. 2001; 35(3):150-6.
    View in: PubMed
    Score: 0.059
  51. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry. 2000 Sep; 157(9):1423-8.
    View in: PubMed
    Score: 0.057
  52. Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry. 2000 Sep; 12(3):137-40.
    View in: PubMed
    Score: 0.057
  53. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord. 2000 Aug; 59(2):119-26.
    View in: PubMed
    Score: 0.057
  54. Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians. Can J Psychiatry. 2000 Jun; 45(5):476-81.
    View in: PubMed
    Score: 0.056
  55. Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression: a survey of current "next-step" practices. J Clin Psychiatry. 2000 Jun; 61(6):403-8.
    View in: PubMed
    Score: 0.056
  56. Compounds containing cytosolic choline in the basal ganglia: a potential biological marker of true drug response to fluoxetine. Am J Psychiatry. 1999 Oct; 156(10):1638-40.
    View in: PubMed
    Score: 0.054
  57. Efficacy of fluvoxamine in the treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry. 1999 Sep; 60(9):580-3.
    View in: PubMed
    Score: 0.054
  58. Open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder. J Clin Psychopharmacol. 1999 Aug; 19(4):329-35.
    View in: PubMed
    Score: 0.053
  59. Patterns of axis I comorbidity in early-onset versus late-onset major depressive disorder. Biol Psychiatry. 1999 Jul 15; 46(2):202-11.
    View in: PubMed
    Score: 0.053
  60. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999 Apr; 60(4):221-5.
    View in: PubMed
    Score: 0.052
  61. Strategies for augmentation of SSRI treatment: a survey of an academic psychopharmacology practice. Harv Rev Psychiatry. 1999 Mar-Apr; 6(6):322-6.
    View in: PubMed
    Score: 0.052
  62. Axis I and Axis II disorder comorbidity in unipolar depression with anger attacks. J Affect Disord. 1999 Jan-Mar; 52(1-3):217-23.
    View in: PubMed
    Score: 0.051
  63. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998 Jul 15; 44(2):77-87.
    View in: PubMed
    Score: 0.049
  64. Outcome definitions and predictors in depression. Psychother Psychosom. 1998 Jul-Oct; 67(4-5):266-70.
    View in: PubMed
    Score: 0.049
  65. Course and treatment of atypical depression. J Clin Psychiatry. 1998; 59 Suppl 18:5-9.
    View in: PubMed
    Score: 0.048
  66. Social phobia, avoidant personality disorder and atypical depression: co-occurrence and clinical implications. Psychol Med. 1997 May; 27(3):627-33.
    View in: PubMed
    Score: 0.046
  67. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry. 1997 Mar; 154(3):426-8.
    View in: PubMed
    Score: 0.045
  68. Consumption of alcohol, nicotine, and caffeine among depressed outpatients. Relationship with response to treatment. Psychosomatics. 1996 Nov-Dec; 37(6):518-22.
    View in: PubMed
    Score: 0.044
  69. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes? Biol Psychiatry. 1996 Oct 15; 40(8):691-6.
    View in: PubMed
    Score: 0.044
  70. Cynicism, hostility, and suicidal ideation in depressed outpatients. J Nerv Ment Dis. 1996 Oct; 184(10):607-10.
    View in: PubMed
    Score: 0.044
  71. Are study dropouts different from completers? Biol Psychiatry. 1996 Oct 01; 40(7):668-70.
    View in: PubMed
    Score: 0.044
  72. Hypochondriacal concerns in depressed outpatients. Psychosom Med. 1996 Jul-Aug; 58(4):314-20.
    View in: PubMed
    Score: 0.043
  73. Attention deficit hyperactivity disorder in childhood among adults with major depression. Psychiatry Res. 1996 Jun 01; 62(3):213-9.
    View in: PubMed
    Score: 0.043
  74. Outpatients with DSM-III-R versus DSM-IV melancholic depression. Compr Psychiatry. 1996 Jan-Feb; 37(1):37-9.
    View in: PubMed
    Score: 0.042
  75. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995 Oct; 152(10):1500-3.
    View in: PubMed
    Score: 0.041
  76. Social adjustment does not predict depressive relapse during continuation fluoxetine therapy. J Affect Disord. 1995 May 17; 34(2):73-7.
    View in: PubMed
    Score: 0.040
  77. Gender differences in personality disorders. Am J Psychiatry. 1995 Apr; 152(4):579-82.
    View in: PubMed
    Score: 0.039
  78. The Mini-Mental State Examination among adult outpatients with major depressive disorder. Psychother Psychosom. 1995; 63(3-4):207-11.
    View in: PubMed
    Score: 0.039
  79. The relationship between age and personality disorders in depressed outpatients. J Nerv Ment Dis. 1995 Jan; 183(1):43-4.
    View in: PubMed
    Score: 0.039
  80. Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacol Bull. 1995; 31(2):223-6.
    View in: PubMed
    Score: 0.039
  81. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry. 1994 Sep; 151(9):1372-4.
    View in: PubMed
    Score: 0.038
  82. Childhood psychopathology retrospectively assessed among adults with early onset major depression. J Affect Disord. 1994 Jul; 31(3):165-71.
    View in: PubMed
    Score: 0.037
  83. Norms for depressed patients for the California verbal learning test: associations with depression severity and self-report of cognitive difficulties. Arch Clin Neuropsychol. 1994 Jan; 9(1):81-8.
    View in: PubMed
    Score: 0.036
  84. Conditional probability of response or nonresponse of placebo compared with antidepressants or St John's Wort in major depressive disorder. J Clin Psychopharmacol. 2013 Dec; 33(6):827-30.
    View in: PubMed
    Score: 0.036
  85. The influence of DST and TRH test administration on depression assessments: a controlled study. Biol Psychiatry. 1993 Nov 01; 34(9):650-3.
    View in: PubMed
    Score: 0.036
  86. Drug interactions in psychopharmacology. Psychiatr Clin North Am. 1993 Sep; 16(3):647-71.
    View in: PubMed
    Score: 0.035
  87. Anger attacks in unipolar depression, Part 2: Neuroendocrine correlates and changes following fluoxetine treatment. Am J Psychiatry. 1993 Aug; 150(8):1164-8.
    View in: PubMed
    Score: 0.035
  88. Anger attacks in unipolar depression, Part 1: Clinical correlates and response to fluoxetine treatment. Am J Psychiatry. 1993 Aug; 150(8):1158-63.
    View in: PubMed
    Score: 0.035
  89. High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord. 1992 Aug; 25(4):229-34.
    View in: PubMed
    Score: 0.033
  90. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand. 1992 Jul; 86(1):42-5.
    View in: PubMed
    Score: 0.033
  91. Anger attacks in depressed outpatients and their response to fluoxetine. Psychopharmacol Bull. 1991; 27(3):275-9.
    View in: PubMed
    Score: 0.029
  92. The antidepressant potential of oral S-adenosyl-l-methionine. Acta Psychiatr Scand. 1990 May; 81(5):432-6.
    View in: PubMed
    Score: 0.028
  93. Neuroendocrine effects of S-adenosyl-L-methionine, a novel putative antidepressant. J Psychiatr Res. 1990; 24(2):177-84.
    View in: PubMed
    Score: 0.027
  94. Dehydroepiandrosterone-sulfate/cortisol ratio in panic disorder. Psychiatry Res. 1989 Jun; 28(3):345-50.
    View in: PubMed
    Score: 0.026
  95. Association of a polymorphism near CREB1 with differential aversion processing in the insula of healthy participants. Arch Gen Psychiatry. 2008 Aug; 65(8):882-92.
    View in: PubMed
    Score: 0.025
  96. Early symptomatic worsening during treatment with fluoxetine in major depressive disorder: prevalence and implications. J Clin Psychiatry. 2007 Jan; 68(1):52-7.
    View in: PubMed
    Score: 0.022
  97. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006 Sep; 31(9):1841-53.
    View in: PubMed
    Score: 0.021
  98. The prevalence and clinical correlates of anger attacks during depressive episodes in bipolar disorder. J Affect Disord. 2004 Apr; 79(1-3):291-5.
    View in: PubMed
    Score: 0.018
  99. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004 Feb; 25(1):119-42.
    View in: PubMed
    Score: 0.018
  100. Axis III disorders in treatment-resistant major depressive disorder. Psychiatry Res. 2003 May 30; 118(2):183-8.
    View in: PubMed
    Score: 0.017
  101. When should a trial of fluoxetine for major depression be declared failed? Am J Psychiatry. 2003 Apr; 160(4):734-40.
    View in: PubMed
    Score: 0.017
  102. Treatment-resistant depression and Axis II comorbidity. Psychother Psychosom. 2002 Sep-Oct; 71(5):269-74.
    View in: PubMed
    Score: 0.016
  103. Treatment resistant depression and axis I co-morbidity. Psychol Med. 2001 Oct; 31(7):1223-9.
    View in: PubMed
    Score: 0.015
  104. Dysfunctional attitudes and poor problem solving skills predict hopelessness in major depression. J Affect Disord. 1999 Sep; 55(1):45-9.
    View in: PubMed
    Score: 0.013
  105. Basal ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 1997 Apr 15; 41(8):837-43.
    View in: PubMed
    Score: 0.011
  106. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry. 1992 Nov; 149(11):1592-4.
    View in: PubMed
    Score: 0.008
  107. Perceptual asymmetry, plasma cortisol, and response to treatment in depressed outpatients. Biol Psychiatry. 1991 Oct 01; 30(7):703-10.
    View in: PubMed
    Score: 0.008
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.